Clinical Trial

Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to determine the safety and efficacy of clascoterone cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-05-05; most recent amendment 2025-07-03.
Status change: Not Yet Recruiting → Recruiting 2024-05-31
Trial Details
NCT Number NCT06403501
Lead Sponsor Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Conditions Acne Vulgaris
Enrollment 692 participants
Start Date 2024-05-20
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2025-07-09